When Dr. Avery Brown's team at NYU Langone compared two paths to serious weight loss, the gap was stark: people who had sleeve gastrectomy or gastric bypass lost an average of 58 pounds over two years. Those taking GLP-1 drugs like semaglutide or tirzepatide lost about 12 pounds.
That's not a minor difference. It's the difference between 24% total weight loss and 4.7%. And it matters because millions of Americans are now betting on one approach or the other to tackle a problem that affects 40% of U.S. adults.
Why the Real World Looks Different from the Lab
Clinical trials make GLP-1 drugs look more promising—showing 15% to 21% weight loss. But when researchers dug into actual medical records from nearly 51,000 patients treated between 2018 and 2024, the numbers shifted. Even patients who stuck with GLP-1 therapy for a full year averaged only 7% weight loss.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxThe culprit isn't the drug itself. It's what happens in real life: side effects make people queasy, costs pile up, and motivation fades. About 70% of GLP-1 patients stop taking the medication within a year. By year two, that figure climbs to 72%. Surgery patients, by contrast, can't really "stop" their treatment—the physical change is permanent.
"GLP-1 patients may need to adjust their expectations, adhere more closely to treatment, or opt for metabolic and bariatric surgery to achieve desired results," Brown said. It's a straightforward assessment: if you want substantial, lasting weight loss, surgery works harder and longer.
This gap between controlled trials and everyday outcomes is crucial. Millions of Americans have tried GLP-1 drugs—about 12% of the population has used one at some point, and 6% are currently taking them. But if most people quit within a year and see minimal results while they're on it, the real-world benefit looks very different from what the headlines promised.
A Tool That's Barely Being Used
Here's the paradox: bariatric surgery is far more effective, yet it remains dramatically underused. More than 270,000 metabolic and bariatric procedures happened in 2023, which sounds like a lot until you realize it represents only 1% of people who actually qualify by BMI standards.
Part of this is perception. Surgery feels permanent and scary. Medication feels like a gentler first step. But the data suggests that for people who need substantial weight loss—and who can access surgery—waiting for a pill to work might mean waiting in vain.
Dr. Karan Chhabra, the study's senior author, flagged the next frontier: understanding which patients should try which approach, and how much out-of-pocket costs are actually driving people away from both options. The picture is incomplete. Some people might do well on GLP-1 drugs if they could afford them without side effects derailing them. Others might benefit from surgery combined with medication. The researchers want to know which is which.
For now, the message is clear: if you're struggling with weight loss and considering your options, surgery delivers results that medication alone, in the real world, typically doesn't match. What comes next is figuring out how to make both tools work better—and get them to the people who need them.
